These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 22867720)

  • 1. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
    Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
    Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice.
    Farag MM; Hoyler B; Encke J; Stremmel W; Weigand K
    Vaccine; 2010 Dec; 29(2):200-6. PubMed ID: 21050902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
    Shimizu Y; Guidotti LG; Fowler P; Chisari FV
    J Immunol; 1998 Nov; 161(9):4520-9. PubMed ID: 9794377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective functional deficit in dendritic cell--T cell interaction is a crucial mechanism in chronic hepatitis B virus infection.
    Zheng BJ; Zhou J; Qu D; Siu KL; Lam TW; Lo HY; Lee SS; Wen YM
    J Viral Hepat; 2004 May; 11(3):217-24. PubMed ID: 15117323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.
    Akbar SM; Yoshida O; Chen S; Cesar AJ; Abe M; Matsuura B; Hiasa Y; Onji M
    Antivir Ther; 2010; 15(6):887-95. PubMed ID: 20834101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
    Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
    Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B.
    Akbar SM; Furukawa S; Horiike N; Abe M; Hiasa Y; Onji M
    J Viral Hepat; 2011 Jun; 18(6):408-14. PubMed ID: 20487261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
    Zhou C; Peng G; Jin X; Tang J; Chen Z
    Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
    Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
    Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection.
    Ren F; Hino K; Yamaguchi Y; Funatsuki K; Hayashi A; Ishiko H; Furutani M; Yamasaki T; Korenaga K; Yamashita S; Konishi T; Okita K
    J Med Virol; 2003 Nov; 71(3):376-84. PubMed ID: 12966542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and humoral immune response to a third generation hepatitis B vaccine.
    Schumann A; Fiedler M; Dahmen U; Grosse-Wilde H; Roggendorf M; Lindemann M
    J Viral Hepat; 2007 Aug; 14(8):592-8. PubMed ID: 17650294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
    Oka Y; Akbar SM; Horiike N; Joko K; Onji M
    Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of dendritic cell-based immunization against HBV in transgenic mice.
    Jiang WZ; Fan Y; Liu X; Zhang YL; Wen JJ; Hao WL; Qian M
    Antiviral Res; 2008 Jan; 77(1):50-5. PubMed ID: 17897731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.